Skip to main content

Table 1 Clinicopathologic and treatment characteristics of 184 patients with mid/low rectal cancer

From: Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial

Variable TME group [cases (%)] CCRT + TME group [cases (%)] P value
Total 94 90  
Age (years)
 ≤ 60 62 (66.0) 64 (71.1) 0.452
 > 60 32 (34.0) 26 (28.9)  
Sex 0.273
 Male 51 (54.3) 56 (62.2)  
 Female 43 (45.7) 34 (37.8)  
DAV (cm) 0.290
 ≤ 5 47 (50.0) 52 (57.8)  
 > 5 47 (50.0) 38 (42.2)  
cTNM stage 0.097
 II 48 (51.1) 33 (36.7)  
 III 46 (48.9) 57 (63.3)  
Type of resection 0.849
 LAR 67 (71.3) 63 (70.0)  
 APR 27 (28.7) 27 (30.0)  
pT stage < 0.001
 pT0–2 22 (23.4) 56 (62.2)  
 pT3–4 72 (76.6) 34 (37.8)  
pN stage 0.005
 pN0 55 (58.5) 70 (77.8)  
 pN1–2 39 (41.5) 20 (22.2)  
pTNM stage < 0.001
 pT0N0M0 0 32 (35.6)  
 pT1–2N0M0 16 (17.0) 17 (18.9)  
 pT3–4N0M0 39 (41.5) 21 (23.3)  
 pT1–4N1–2M0 39 (41.5) 20 (22.2)  
Adjuvant chemotherapy < 0.001
 Yes 61 (64.9) 79 (87.8)  
 No 33 (35.1) 11 (12.2)  
Cycles of perioperative chemotherapy
 1–7 52 (55.3) 56 (62.2) 0.342
 8 42 (44.7) 34 (37.8)  
  1. TME, total mesorectal excision; CCRT, concurrent chemoradiotherapy; DAV, distance of the inferior tumor margin from the anal verge; cTNM stage, clinical tumor-node-metastasis classification; LAR, low anterior resection; APR, abdominoperineal resection; pTNM stage, pathologic tumor-node-metastasis classification; pT stage, pathologic tumor stage; pN stage, pathologic node stage